Table 1.
Cytotoxicity and antiviral activity of studied compounds against enveloped dsDNA viruses (M ± SD).
| Cmpd | EC50, μMa |
CC50, μM |
|||
|---|---|---|---|---|---|
| VZV, TK+ strain | VZV, TK– strain | CMV, AD-169 | CMV, Davis |
HEL cells | |
| 11a | 0.42 ± 0.08 (>238)b | 15.9 ± 9.8 (>6) | 54.69 (>2) | 42.3 ± 3.4 (>2) | >100 |
| 11b | 0.200 ± 0.099 (>500) | 11.3 ± 14.2 (>8) | >100 | >100 | >100 |
| 11c | 0.68 ± 0.11 (74) | 15.2 ± 2.5 (3) | >100 | 10.4 ± 0.8 (5) | 50.3 ± 2.4 |
| 12a | 8.7 ± 6.7 (>11) | >100 | >100 | >100 | >100 |
| 12b | >20 | >20 | >100 | >100 | >100 |
| 12c | 10.7 ± 1.3 (>9) | 15.1 ± 7.0 (>6) | >20 | 20 | >100 |
| 12d | >100 | >100 | >100 | >100 | >100 |
| 13 | >100 | >100 | >100 | >100 | >100 |
| 14 | >100 | >100 | >100 | >100 | >100 |
| 16a | >100 | >100 | >100 | >100 | >100 |
| 16b | >100 | >100 | >100 | >100 | >100 |
| 17 | >100 | >100 | >100 | >100 | >100 |
| 18 | >20 | 13.3 ± 0.9 (>8) | >100 | 9.2 ± 1.7 (>11) | >100 |
| 19 | >100 | >100 | >100 | >100 | >100 |
| 20 | >20 | >20 | 48.9 (>2) | 44.72 (>2) | >100 |
| 23 | >100 | 64.4 (>1.5) | >20 | >100 | >100 |
| Acyclovir | 12.0 ± 9.7 | 56 ± 33 | – | – | >300 |
| Brivudine | 0.034 ± 0.015 | 0.42 ± 0.26 | – | – | >300 |
| Ganciclovir | – | – | 19 ± 14 | 1.79 ± 0.75 | >300 |
| Cidofovir | – | – | 1.31 ± 0.1 | 0.61 ± 0.29 | >300 |
a
Effective concentration required to reduce virus plaque formation by 50%.
b
Selectivity index (SI) is shown in brackets.